» Articles » PMID: 29721726

Association Between Serum Lipid Levels, Osteoprotegerin and Depressive Symptomatology in Psychotic Disorders

Overview
Specialties Neurology
Psychiatry
Date 2018 May 4
PMID 29721726
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Although the relationship between positive and negative symptoms of psychosis and dyslipidemia has been thoroughly investigated in recent studies, the potential link between depression and lipid status is still under-investigated. We here examined the association between lipid levels and depressive symptomatology in patients with psychotic disorders, in addition to their possible inflammatory associations. Participants (n = 652) with the following distribution: schizophrenia, schizophreniform and schizoaffective disorder (schizophrenia group, n = 344); bipolar I, II, NOS, and psychosis NOS (non-schizophrenia group, n = 308) were recruited consecutively from the Norwegian Thematically Organized Psychosis (TOP) Study. Clinical data were obtained by Positive and Negative Syndrome Scale (PANSS), and Calgary Depression Scale for Schizophrenia (CDSS). Blood samples were analyzed for total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), C-reactive protein (CRP), soluble tumor necrosis factor receptor 1(sTNF-R1), osteoprotegerin (OPG), and interleukin 1 receptor antagonist (IL-1Ra). After adjusting for age, gender, BMI, smoking, and dyslipidemia-inducing antipsychotics, TC and LDL scores showed significant associations with depression [β = 0.13, p = 0.007; β = 0.14, p = 0.007], and with two inflammatory markers: CRP [β = 0.14, p = 0.007; β = 0.16, p = 0.007] and OPG [β = 0.14, p = 0.007; β = 0.11, p = 0.007]. Total model variance was 17% for both analyses [F(12, 433) = 8.42, p < 0.001; F(12, 433) = 8.64, p < 0.001]. Current findings highlight a potential independent role of depression and inflammatory markers, CRP and OPG in specific, in the pathophysiology of dyslipidemia in psychotic disorders.

Citing Articles

Differences in the Prevalence and Clinical Correlates Between Early-Onset and Late-Onset Major Depressive Disorder Patients with Comorbid Abnormal Lipid Metabolism.

Huang X, Wu A, Zhang X Metabolites. 2025; 15(2).

PMID: 39997742 PMC: 11857319. DOI: 10.3390/metabo15020117.


Effect of RANKL on Lower Depressive Symptoms In Hemodialysis Patients.

Lee D, Chung Y, Kim B, Lee J, Lee K, Lee Y Calcif Tissue Int. 2024; 115(2):124-131.

PMID: 38878178 DOI: 10.1007/s00223-024-01215-2.


Association of clinical variables and thyroid-stimulating hormone with psychotic symptoms in patients with first-episode and drug-naïve major depressive disorder with elevated fasting blood glucose: preliminary exploratory study with a large sample.

Yang Q, Wang Q, Peng P, Liu T, Zhang X BJPsych Open. 2024; 10(3):e99.

PMID: 38699891 PMC: 11094438. DOI: 10.1192/bjo.2024.53.


Lipid Biomarker Research in Bipolar Disorder: A Scoping Review of Trends, Challenges, and Future Directions.

Hiller J, Jangmo A, Tesli M, Jaholkowski P, Hoseth E, Steen N Biol Psychiatry Glob Open Sci. 2023; 3(4):594-604.

PMID: 37881590 PMC: 10593953. DOI: 10.1016/j.bpsgos.2023.07.004.


Selected Parameters of Bone Turnover in Neuroendocrine Tumors-A Potential Clinical Use?.

Strzelczyk J, Wojcik-Giertuga M, Strzelczyk J, Senkowska A, Biernacki K, Kos-Kudla B J Clin Med. 2023; 12(14).

PMID: 37510722 PMC: 10380215. DOI: 10.3390/jcm12144608.


References
1.
Addington D, Addington J, Maticka-Tyndale E . Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994; 11(3):239-44. DOI: 10.1016/0920-9964(94)90017-5. View

2.
Rethorst C, Bernstein I, Trivedi M . Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry. 2015; 75(12):e1428-32. PMC: 4309548. DOI: 10.4088/JCP.14m09009. View

3.
Pan A, Keum N, Okereke O, Sun Q, Kivimaki M, Rubin R . Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012; 35(5):1171-80. PMC: 3329841. DOI: 10.2337/dc11-2055. View

4.
Suttajit S, Pilakanta S . Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia. Neuropsychiatr Dis Treat. 2013; 9:941-6. PMC: 3709830. DOI: 10.2147/NDT.S47450. View

5.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View